FDA Clearance Tracker · P110021-S026
EDWARDS SAPIEN TRANSCATHETER HEART VALVE AND TRANSFEMORAL AND TRANSAPICAL ACCESSORIES
Last checked: Nov 20, 2026Latest source record: Sep 23, 2013 (this decision)Source: openFDAMethods & limitations
Decided
Sep 23, 2013
Approved
Time to decision
26 days
Received Aug 28, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P110021-S026
- Device name
- EDWARDS SAPIEN TRANSCATHETER HEART VALVE AND TRANSFEMORAL AND TRANSAPICAL ACCESSORIES
- Applicant
- Edwards Lifesciences, LLC
- Applicant location
- Irvine, CA
- Received
- Aug 28, 2013
- Decided
- Sep 23, 2013
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P110021
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR REMOVAL OF ACCESS APPROACH FROM DEVICE LABELING. THE DEVICE IS INDICATED FOR PATIENTS WITH SEVERE SYMPTOMATIC CALCIFIED NATIVE AORTIC VALVE STENOSIS WITHOUT SEVERE AORTIC INSUFFICIENCY AND WITH EJECTION FRACTION > 20% WHO HAVE BEEN EXAMINED BY A HEART TEAM INCLUDING AN EXPERIENCED CARDIAC SURGEON AND A CARDIOLOGIST AND FOUND TO BE: 1) INOPERABLE AND IN WHOM EXISTING CO-MORBIDITIES WOULD NOT PRECLUDE THE EXPECTED BENEFIT FROM CORRECTION OF THE AORTIC STENOSIS; OR 2) BE OPERATIVE CANDIDATES FOR AORTIC VALVE REPLACEMENT BUT WHO HAVE A PREDICTED OPERATIVE RISK SCORE >= 8% OR ARE JUDGED BY THE HEART TEAM TO BE AT A >= 15% RISK OF MORTALITY FOR SURGICAL AORTIC VALVE REPLACEMENT.
Source documents
Other decisions for Edwards Lifesciences, LLC
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- PASCAL Precision Transcatheter Valve Repair SystemPMA supplement
P220003-S029 · Decided Oct 20, 2026 · 180 days after receipt · Panel Track
Device type: Tricuspid valve repair device, percutaneously delivered (NPS) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.